Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. Show more

Location: 3 World Trade Center, New York, NY, 10007, United States | Website: https://metsera.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

3.746B

52 Wk Range

$12.30 - $47.40

Previous Close

$35.66

Open

$35.80

Volume

1,104,121

Day Range

$34.67 - $36.53

Enterprise Value

3.216B

Cash

530.9M

Avg Qtr Burn

-44.49M

Insider Ownership

17.71%

Institutional Own.

84.26%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.